Immatics (IMTX) Other Non-Current Liabilities (2019 - 2025)
Immatics (IMTX) posted Other Non-Current Liabilities of $7.8 million for Q3 2025, up 5488.71% sequentially from $139900.6 in Q1 2025, and down 51.78% YoY from $16.2 million in Q3 2024.
Immatics (IMTX) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Immatics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $7.8 million in Q3 2025.
- Quarterly Other Non-Current Liabilities fell 51.78% year-over-year to $7.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.8 million (down 51.78% YoY) and the FY2024 annual result came in at $1.9 million, up 43174.82% from the prior year.
- Other Non-Current Liabilities advanced to $7.8 million in Q3 2025 per IMTX's latest filing, from $139900.6 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $19.5 million in Q1 2024 and troughed at $4303.8 in Q4 2023.
- A 5-year average of $3.1 million and a median of $77790.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 74378.01% in 2024, then tumbled 99.28% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $77790.0 in 2021, then slumped by 44.92% to $42850.4 in 2022, then sank by 89.96% to $4303.8 in 2023, then surged by 42854.77% to $1.8 million in 2024, then soared by 322.93% to $7.8 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $7.8 million, $139900.6, and $1.8 million for Q3 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 139,900.63 |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 16.22 Mn |
| Mar 31, 2024 | 19.50 Mn |
| Dec 31, 2023 | 4,303.76 |
| Sep 30, 2023 | 21,771.81 |
| Jun 30, 2023 | 28,312.03 |
| Mar 31, 2023 | 35,420.28 |
| Dec 31, 2022 | 42,850.39 |
| Sep 30, 2022 | 55,455.09 |
| Jun 30, 2022 | 62,956.34 |
| Mar 31, 2022 | 70,707.28 |
| Dec 31, 2021 | 77,790.02 |
| Sep 30, 2021 | 3.63 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | 1.17 Mn |
| Dec 31, 2020 | 60,806.78 |
| Sep 30, 2020 | 2.38 Mn |
| Jun 30, 2020 | 1.59 Mn |